MannKind Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MannKind Corporation is a biopharmaceutical company primarily engaged in the development and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its main products and services include the manufacture and sale of Afrezza, a rapid-acting inhalable insulin for diabetes management; advanced proprietary technologies such as the Technosphere platform for drug delivery; and development of product candidates for respiratory and other systemic diseases. MannKind offers pharmaceutical formulations, delivery devices, and licensing of its inhalation technology platforms. The company operates mainly in the United States but has strategic partnerships allowing its products and technologies to reach broader markets internationally. Founded in 1991 and headquartered in Valencia, California, MannKind continues to focus on innovation in pulmonary drug delivery systems and diabetes treatment solutions. Recent major company developments include strategic partnerships aimed at expanding the commercialization and distribution of Afrezza, along with ongoing research collaborations to enhance its proprietary Technosphere platform. Over the last one to two years, MannKind has also pursued product pipeline expansions and has announced progress in clinical trials targeting pulmonary and systemic diseases beyond diabetes. The company has not undergone any name changes or major reorganizations but has actively refined its operational focus to strengthen its market position within the biopharmaceutical industry. MannKind's business segments include pharmaceutical product development and manufacturing, technology licensing, and strategic alliances. Its target customers encompass healthcare providers, patients with chronic diseases such as diabetes, and biotechnology collaborators. The company operates as an independent publicly traded entity under the ticker symbol MNKD. It manages subsidiaries related to product development and technology commercialization to support its core operations.
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
US FDA approves MannKind's inhaled insulin for children
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind to Present at Jefferies Global Healthcare Conference
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
The $59B Quiet Shift Reshaping How Patients Access Care
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind: It's Complicated
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases